| 抗程序性死亡受体1单克隆抗体体外细胞因子释放综合征风险评估 |
| |
| 引用本文： | 彭伟,刘忠,张贵民,赵丽丽.抗程序性死亡受体1单克隆抗体体外细胞因子释放综合征风险评估[J].现代药物与临床,2019,42(8):1520-1522. |
| |
| 作者姓名： | 彭伟 刘忠 张贵民 赵丽丽 |
| |
| 作者单位： | 山东新时代药业哺乳动物细胞高效表达国家工程实验室, 山东 临沂 273400,山东新时代药业哺乳动物细胞高效表达国家工程实验室, 山东 临沂 273400,山东新时代药业哺乳动物细胞高效表达国家工程实验室, 山东 临沂 273400,山东新时代药业哺乳动物细胞高效表达国家工程实验室, 山东 临沂 273400 |
| |
| 摘 要： | 目的 选择合适的方法评价抗程序性死亡受体1（PD-1）单克隆抗体在体外引起细胞因子释放的风险。方法 通过抗体与人PBMC细胞共培养6、24 h，并用流式技术评估重组人源化抗PD-1单克隆抗体（F520）和已上市抗PD-1单克隆抗体Opdivo、Keytruda是否存在引起细胞因子释放综合征（cytokine release syndrome，CRS）的风险。结果 成功建立了采用人PBMC细胞在体外进行抗PD-1单克隆抗体细胞因子释放的评价技术。结论 与人PBMC细胞的共培养6、24 h，F520、Opdivo和Keytruda在体外均不存在引起CRS的风险。
|
| 关 键 词： | 抗PD-1单克隆抗体 F520 细胞因子释放综合征 |
| 收稿时间： | 2019/1/24 0:00:00 |
CRS risk assessment of anti-PD-1 monoclonal antibody in vitro |
| |
| PENG Wei,LIU Zhong,ZHANG Guimin and ZHAO Lili.CRS risk assessment of anti-PD-1 monoclonal antibody in vitro[J].Drugs & Clinic,2019,42(8):1520-1522. |
| |
| Authors: | PENG Wei LIU Zhong ZHANG Guimin and ZHAO Lili |
| |
| Institution: | National Engineering Lab. for High Efficiency Expression of the Mammalian Cells, Shandong New Time Pharmaceutical Co. Ltd., Linyi 273400, China,National Engineering Lab. for High Efficiency Expression of the Mammalian Cells, Shandong New Time Pharmaceutical Co. Ltd., Linyi 273400, China,National Engineering Lab. for High Efficiency Expression of the Mammalian Cells, Shandong New Time Pharmaceutical Co. Ltd., Linyi 273400, China and National Engineering Lab. for High Efficiency Expression of the Mammalian Cells, Shandong New Time Pharmaceutical Co. Ltd., Linyi 273400, China |
| |
| Abstract: | Objective Choose the appropriate method to evaluate cytokine release syndrome induced by anti-PD1 monoclonal antibody in vitro. Methods PBMC Cells were cocultured with mAb for 6 and 24 hours. Using FACS, we evaluated the risk of cytokine release syndrome induced by F520, Opdivo and Keytruda.Results Successfully established the method to evaluate cytokine release syndrome induced by anti-PD1 monoclonal antibody in vitro.Conclusion Cocultured with PBMC Cells for 6 and 24 hours, the results strongly emphasized that F520, Opdivo and Keytruda could not induce cytokine release syndrome. |
| |
| Keywords: | Anti-PD1 monoclonal antibody F520 cytokine release syndrome |
|
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
| 点击此处可从《现代药物与临床》下载免费的PDF全文 |
|
